

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mark James BAMFORD, et al.

Serial No. 10/598,759

Group No.: 1624

Filed: September 11, 2006

Examiner: Brenda L. Coleman

For: BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

Office of Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION FOR WITHDRAWAL FROM ISSUE (37 CFR §1.313(c)(2))


Applicant(s) hereby petition to withdraw from issue the captioned U.S. patent application under the provisions of 37 C.F.R. §1.313(C)(2). Applicant(s) wish to withdraw this application from issue in order to permit the Office to consider a concurrent submission of a Request for Continued Examination pursuant to §1.114.

The Office's favorable consideration of this petition is respectfully requested.

A fee for this petition under 37 C.F.R. §1.17(h) in the amount of \$130 is authorized to be charged against Deposit Account 07-1392.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to Deposit Account 07-1392.

Respectfully Submitted,



Bonnie L. Deppenbrock
Attorney of Record:
Registration No. 28,209

Date: May 19, 2009

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988